loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Vafidemstat

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Vafidemstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oryzon Presents Final PORTICO Vafidemstat BPD Trial Data
    Oryzon Presents Final PORTICO Vafidemstat BPD Trial Data

    23 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/23/2951325/0/en/ORYZON-Presents-the-Final-Data-From-PORTICO-a-Global-Phase-IIb-Vafidemstat-Trial-in-Borderline-Personality-Disorder-BPD-at-the-European-College-of-Neuropsychopharmacology-ECNP-Cong.html

    GLOBENEWSWIRE
    23 Sep 2024
    Share Share
    ORYZON Receives Patent Intent For Vafidemstat In Borderline Personality
    ORYZON Receives Patent Intent For Vafidemstat In Borderline Personality

    11 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/11/2944681/0/en/ORYZON-Receives-Intention-to-Grant-Communication-for-Patent-Relating-to-the-Use-of-Vafidemstat-in-Borderline-Personality-Disorder.html

    GLOBENEWSWIRE
    11 Sep 2024
    Share Share
    ORYZON Strengthens Patent Portfolio for Vafidemstat with New Grant
    ORYZON Strengthens Patent Portfolio for Vafidemstat with New Grant

    03 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/03/2939652/0/en/ORYZON-Continues-to-Strengthen-its-Patent-Portfolio-for-Vafidemstat-with-Additional-Decision-to-Grant-Communications.html

    GLOBENEWSWIRE
    03 Sep 2024
    Share Share
    ORYZON To Receive Two Important Patents For Vafidemstat In Japan
    ORYZON To Receive Two Important Patents For Vafidemstat In Japan

    08 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/08/2909570/0/en/ORYZON-Receives-Decision-to-grant-for-Two-Important-Patents-for-Vafidemstat-in-Japan.html

    GLOBENEWSWIRE
    08 Jul 2024
    Share Share
    ORYZON Present of Final Data From Vafidemstat’s Global Phase IIb Trial
    ORYZON Present of Final Data From Vafidemstat’s Global Phase IIb Trial

    26 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/26/2904462/0/en/ORYZON-Announces-Presentation-of-Final-Data-From-PORTICO-Vafidemstat-s-Global-Phase-IIb-Trial-in-Borderline-Personality-Disorder-at-the-37th-ECNP-Annual-Conference.html

    GLOBENEWSWIRE
    26 Jun 2024
    Share Share
    ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
    ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

    22 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/22/2866802/0/en/ORYZON-Secures-Another-Important-Patent-for-its-Lead-CNS-Asset-Vafidemstat.html

    GLOBENEWSWIRE
    22 Apr 2024
    Share Share